At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02652 CF PHARMTECH
Noon Closed 09-04 12:05:00
11.310
-0.490
-4.15%
High12.050Low11.140Vol1.44M
Open12.050D1 Closing11.800Amplitude7.71%
Mkt Cap4.89BTradable Cap3.65BTotal Shares432.00M
T/O16.39MT/O Rate0.44%Tradable Shares323.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
CF PharmTech (SEHK:2652) Stock Pressured By Widening Losses And Thin Profit Clarity
Simply Wall St.  ·  09-01 23:32
CF PharmTech (SEHK:2652) Stock Pressured By Widening Losses And Thin Profit Clarity
CF Pharmtech Reports Interim Revenue of RMB 210 Million, Up 2.1% Year-on-Year
Stock News  ·  08-31
CF Pharmtech Reports Interim Revenue of RMB 210 Million, Up 2.1% Year-on-Year
CF PharmTech FY26 H1 Net Loss Widens to RMB 10.51 Million; Revenue Rises 2.08% to RMB 210.15 Million
Reuters  ·  08-31
CF PharmTech FY26 H1 Net Loss Widens to RMB 10.51 Million; Revenue Rises 2.08% to RMB 210.15 Million
CF Pharmtech Wraps Up Issuance of 21.75 Million New H-Shares
Stock News  ·  08-28
CF Pharmtech Wraps Up Issuance of 21.75 Million New H-Shares
CF PharmTech Releases Revised Articles of Association: Capital Structure, Governance Framework and Dividend Rules Clarified
Bulletin Express  ·  08-28
CF PharmTech Releases Revised Articles of Association: Capital Structure, Governance Framework and Dividend Rules Clarified
CF PharmTech Files HKEX Next-Day Disclosure Return, Lifts Share Capital with 21,747,700 New H Shares at HKD 13.82 Each
Reuters  ·  08-28
CF PharmTech Files HKEX Next-Day Disclosure Return, Lifts Share Capital with 21,747,700 New H Shares at HKD 13.82 Each
Hong Kong Stock Alert | CF PHARMTECH (02652) Surges Over 20% Intraday on Two New Clinical Approvals for ICF001, Highlighting Long-Acting Inhaled Prodrug Design Edge
Stock News  ·  08-27
Hong Kong Stock Alert | CF PHARMTECH (02652) Surges Over 20% Intraday on Two New Clinical Approvals for ICF001, Highlighting Long-Acting Inhaled Prodrug Design Edge
Hong Kong Stock Movers | CF PHARMTECH (02652) Surges Over 5% as ICF001 Covers Four Major Indications Including IPF and PPF, with Plans to Launch Phase I Trials Domestically and Overseas
Stock News  ·  08-25
Hong Kong Stock Movers | CF PHARMTECH (02652) Surges Over 5% as ICF001 Covers Four Major Indications Including IPF and PPF, with Plans to Launch Phase I Trials Domestically and Overseas
CF PHARMTECH Secures Two Additional Clinical Approvals for ICF001, Expanding Coverage Across Four Major Indications
Stock News  ·  08-24
CF PHARMTECH Secures Two Additional Clinical Approvals for ICF001, Expanding Coverage Across Four Major Indications
CF PHARMTECH (02652) Secures Expanded Clinical Trial Approval for ICF001 Across Additional Indications
Stock News  ·  08-24
CF PHARMTECH (02652) Secures Expanded Clinical Trial Approval for ICF001 Across Additional Indications
CF Pharmtech, - Receives Nmpa Implied Clinical Trial Approvals for Icf001 in Ipf and Ppf
THOMSON REUTERS  ·  08-24
CF Pharmtech, - Receives Nmpa Implied Clinical Trial Approvals for Icf001 in Ipf and Ppf
CF PharmTech Says NMPA Clears Icf001 Trials in IPF, PPF
Reuters  ·  08-24
CF PharmTech Says NMPA Clears Icf001 Trials in IPF, PPF
CF PharmTech Sets 31 August 2026 Board Meeting to Review H1 2026 Results and Potential Interim Dividend
Bulletin Express  ·  08-19
CF PharmTech Sets 31 August 2026 Board Meeting to Review H1 2026 Results and Potential Interim Dividend
CF PharmTech Schedules Board Meeting to Review Interim Results
Reuters  ·  08-19
CF PharmTech Schedules Board Meeting to Review Interim Results
CF Pharmtech Hits 10-Month Low, Raised HKD 295 Million in Quick Placement Amid R&D Spending and Valuation Correction
Deep News  ·  08-13
CF Pharmtech Hits 10-Month Low, Raised HKD 295 Million in Quick Placement Amid R&D Spending and Valuation Correction
Hong Kong Stocks Midday Summary: Hang Seng Index Edges Up 0.07% as Healthcare Sector Leads Gains
Stock News  ·  08-13
Hong Kong Stocks Midday Summary: Hang Seng Index Edges Up 0.07% as Healthcare Sector Leads Gains
CF Pharmtech Rises Over 5% at Midday After Completing Placement of 21.7 Million New H Shares
Deep News  ·  08-13
CF Pharmtech Rises Over 5% at Midday After Completing Placement of 21.7 Million New H Shares
CF PHARMTECH Shares Surge Over 5% Following Completion of H-Share Placement, ICF001 Poised to Fill Clinical Gap in PH-ILD Treatment
Stock News  ·  08-13
CF PHARMTECH Shares Surge Over 5% Following Completion of H-Share Placement, ICF001 Poised to Fill Clinical Gap in PH-ILD Treatment
CF PharmTech Completes Placement of 21,747,700 New H Shares at HK$ 13.82 Each
Reuters  ·  08-06
CF PharmTech Completes Placement of 21,747,700 New H Shares at HK$ 13.82 Each
CF PharmTech Maintains 411.98 Million Registered Shares and Confirms Ample Public Float in July 2026 Return
Bulletin Express  ·  08-04
CF PharmTech Maintains 411.98 Million Registered Shares and Confirms Ample Public Float in July 2026 Return
No data available

Introduction

Company Name.
CF PHARMTECH
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
CF PharmTech, Inc. is a China-based company primarily the research and development, production and sale of respiratory drugs and other related medical products. The Company’s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Company's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The Company mainly conducts its business in the domestic market.
Issue price:
--